Phenotypes associated with this allele

• Allele Symbol: Tg(tetO-Ipf1,EGFP)956.6Macd
• Allele Name: transgene insertion 956-6, Raymond J MacDonald
• Allele ID: MGI:3655514
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Pdx1^tm1Macd/Pdx1^tm1Macd Tg(tetO-Ipf1,EGFP)956.6Macd/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	MGI:3655708

Genotype
MGI:3655708

cx1

• Allelic Composition: Pdx1^tm1Macd/Pdx1^tm1Macd; Tg(tetO-Ipf1,EGFP)956.6Macd/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

increased glucagon secretion ( J:101742 )

• in doxycycline-treated mice there is an increase in glucagons-positive cells

decreased insulin secretion ( J:101742 )

• there is a marked reduction in insulin in pancreata of doxycycline-treated mice; after withdrawal of doxycycline, insulin +ve cells are detected in islets of smaller islet-like cell clusters

decreased circulating glucose level ( J:101742 )

• 14 days after doxycycline withdrawal after 14 days of treatment resulted in a significant decrease in blood glucose levels with 4/5 mice becoming normoglycemic by 28 days

increased circulating glucose level ( J:79206 )

• with doxycycline treatment for 21 day, adult rescue mice show a 4-fold increase in fasting blood glucose to diabetic levels

impaired glucose tolerance ( J:79206 , J:101742 )

• adult transgenic rescue animals treated with doxycycline for 14 days exhibit a defective response to glucose challenge compared to wild-type, non mutant transgenic, or untreated rescue mice (J:79206)

• when adult mice are treated with doxycycline for 0, 7, 14, or 21 days, mice show an increased early glucose response within 7 days of start of treatment and ability to recover from glucose challenge is impaired compared to untreated transgenics where glucose levels recover to basal levels within 3 hours; by 14 days of doxycycline treatment, mice have diabetes (J:101742)

endocrine/exocrine glands

abnormal pancreatic beta cell morphology ( J:101742 )

• after 14 or 28 days of dox treatment there are, still present, beta cells which lack insulin

small pancreatic islets ( J:101742 )

• after dox treatment for 14 days, there is a significant decrease in islet area compared to wild-type

abnormal pancreas development ( J:79206 )

• pancreas of transgenic rescue newborn mice is 50% the size of a normal wild-type neonatal pancreas

• treatment of pregnant mice with doxycycline from the first day of pregnancy through parturition prevents formation of the pancreas in mice with the transgenic rescue genotype

• treatment on E11.5 arrests pancreatic development ~36 hours later; at birth the underdeveloped remnant consisted of a large and extended duct with several terminal, aborted, ductal buds with ducts lined with a single layer of primitive epithelial cells and with no acinar or islet tissue

increased glucagon secretion ( J:101742 )

• in doxycycline-treated mice there is an increase in glucagons-positive cells

decreased insulin secretion ( J:101742 )

• there is a marked reduction in insulin in pancreata of doxycycline-treated mice; after withdrawal of doxycycline, insulin +ve cells are detected in islets of smaller islet-like cell clusters

cellular

increased cell proliferation ( J:101742 )

• foci of duct proliferation are present in mice after 14 days of doxycycline treatment and become more prominent with continued treatment